$MNMD reports significant progress, confident financial position
Mar 9th 2023, 9:17 pm
Analyst Summary: Mind Medicine (MindMed) has reported its financial results for the full-year ended December 31, 2022. The company witnessed significant progress in 2022 and expects it to be a transformational year for the company. MindMed remains focused on its mission to deliver novel therapies to treat brain health disorders, believing that it will lead to meaningful improvements in patient outcomes in these major areas of unmet medical need. The company is also confident about its financial position, providing them the ability to fund their programs well beyond these key milestones and into the first half of 2025. MindMed's CEO, Robert Barrow stated, "Our significant progress in 2022 has set the stage for what we expect to be a transformational 2023." He also added, "I am more confident than ever in our ability to continue advancing our organization and development programs." MindMed's guidance for its cash runway is expected to fund its current operating plan into the first half of 2025. The company plans to initiate its first clinical trial of MM-402 in 2023. MindMed aims to be the global leader in the development and delivery of treatments that improve patient outcomes. Investors may listen to the live conference call or visit the company's website for the latest information on the company's financial results.